This descriptive study was designed to ascertain the current heartworm treatment strategies employed by veterinary graduates of a single college of veterinary medicine, to assess the frequency with which each of these treatment strategies is prescribed, and to report the motivation behind the use of these treatment strategies. A survey containing a combination of multiple-choice and open-ended questions was distributed via e-mail with an online link during 2013 to graduates of the University of Georgia College of Veterinary Medicine. Demographic data and opinions regarding treatment for cases of canine heartworm disease (HWD) were obtained, and motivation for recommending different treatment strategies was assessed. Nearly all 170 respondents (99%) indicated that they recommend melarsomine dihydrochloride for first-line treatment of canine HWD. Exercise restriction (80%) and monthly heartworm preventive (75%) were components of the treatment approach to HWD with no clinical signs. The majority of respondents (74%) indicated that when first-line treatment recommendations were declined, they endorsed long-term administration of ivermectin (i.e., "slow-kill" method) despite current American Heartworm Society guidelines that recommend against the use of long-term macrocyclic lactone administration for the monotherapy treatment of canine HWD. Respondents also indicated that owners' financial concerns frequently result in modification of HWD treatment. Routine inclusion of exercise restriction is commonly, but not universally, utilized and may represent an opportunity for improvement in the management of this disease. In addition, when first-line recommendations for heartworm disease treatment are declined, a two-dose melarsomine protocol instead of the slow-kill method should be considered. (J Am Anim Hosp Assoc 2018; 54:246-256.
Introduction
The dog is a highly susceptible host to Dirofilaria immitis, the causative agent of heartworm disease (HWD). Maturation of these worms in the infected dog creates a disease syndrome that includes respiratory signs, cor pulmonale, and right-sided congestive heart failure. In severe and/or untreated cases, HWD can also damage other noncardiopulmonary body systems and ultimately cause death. 1 The disease is considered preventable with the administration of safe, effective macrocyclic lactones (e.g., ivermectin, milbemycin, moxidectin, and selamectin). In spite of the availability of these preventive agents, surveys indicate between 1.2 and 48% of dogs tested by primary care veterinarians are positive for adult cidal treatment protocol includes a two-dose regimen of melarsomine, although this is no longer recommended as the ideal treatment regimen by the AHS. 8 In considering the use of either the two-or three-dose melarsomine regimen, as well as the incorporation of doxycycline, macrocyclic lactones, steroid administration, and exercise restriction, the practitioner has several adulticidal treatment protocols from which to choose. Furthermore, some practitioners may forgo the use of melarsomine altogether, opting for a treatment approach that has come to be known as the slow-kill method.
Slow-kill is a term used to describe heartworm treatment protocols that utilize continuous monthly administration of prophylactic doses of one of the macrocyclic lactones, with or without the addition of doxycycline. The long-term monthly administration of the macrocyclic lactone, ivermectin, has been shown to be adulticidal but requires up to 36 mo for complete D immitis elimination. 9 During this period of monthly drug administration, continued pulmonary and cardiac damage occur. A study of naturally infected dogs treated with monthly ivermectin showed worsening of radiographic pulmonary disease, leading the authors to conclude that slow-kill methods are ill-advised. 10 Another study of experimentally infected dogs treated with monthly ivermectin showed that 25 of 31 dogs had evidence of pulmonary embolism at necropsy.
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Due to the extended opportunity for cardiovascular and pulmonary pathology, the AHS recommends against slow-kill methods for the treatment of canine HWD. 8 The objectives of the present study were to gather information on veterinary practitioners' treatment recommendations for dogs affected by HWD who are presented with and without clinical signs, to determine how often these recommendations agree with AHS guidelines, and to identify the frequency with which owner financial constraints lead to modification of these recommendations. We elicited information about the frequency with which slow-kill methods are recommended in veterinary practice and how often they are used as alternatives to the recommended melarsominebased protocols. We also sought to determine practitioners' potential motivations for the use of slow-kill methods. For this purpose,
we developed an online survey that included questions concerning HWD treatment regimens. Alumni from the University of Georgia,
College of Veterinary Medicine were chosen to participate in the study based upon access to e-mail addresses and ease of survey distribution.
Materials and Methods
The survey consisted of an online questionnaire that was com- 
Results

Respondents
A total of 2,000 graduates were identified to participate in the survey, of whom 1,924 had a valid e-mail address on file. Of these 1,924, 654 graduates (34%) opened the invitation. The 2 wk reminder e-mail was sent to 1,932 e-mail addresses, of which 1,919 were valid.
Of those with valid e-mail addresses, a total of 507 graduates (26%) opened this reminder e-mail. The survey was closed 1 mo after the initial invitation. A total of 170 veterinarians completed the online survey. Three respondents were excluded from analysis because they were not currently practicing veterinary medicine at the time they responded. The overall response rate of those who opened the initial invitation e-mail was 170/654 (26%). The median number of years since graduation of respondents was 10 yr (minimummaximum, 0-59 yr; Figure 1 ). The year of graduation for respondents ranged from 1954 to 2013, and the largest percentage of respondents graduated in 2012 (9.5%). Respondents were not asked to report the city or state in which they were practicing veterinary medicine at the time of the survey. The majority of respondents (65%) indicated that they practice in suburban areas, with the balance divided between metropolitan (28%) and rural (7%) regions. Most respondents (81%) indicated that they work in privately owned practices, with the remainder divided between corporately owned (12%), academic (4%), shelter (2%) and "other" (1%) practices. Finally, the majority (95%) of respondents indicated that they work in small animal practices. A small total percentage of respondents reported that they work in mixed animal (5%) or exotic animal (0.6%) practices.
Respondents reported a median canine caseload of 2,000 cases/ year (minimum-maximum, 100-15,000). The estimated median number of heartworm-positive dogs diagnosed annually was 10 cases/year (minimum-maximum, 0-1,500). Respondents indicated that most dogs diagnosed with HWD each year either had no available history regarding administration of heartworm preventive (38%) or had never been given heartworm preventive (34%). Less frequently, respondents reported that heartworm-positive dogs were given heartworm preventive seasonally with one or more missed doses (17%) or had been given year-round heartworm preventive with one or more missed doses (11%).
HWD Cases with No Clinical Signs
Respondents were asked to identify which of a provided list of with 76% using a three-dose melarsomine protocol (one intramuscular injection followed 1 mo later by two doses 24 hr apart) and the minority (24%) using a two-dose melarsomine protocol (two intramuscular injections of melarsomine, 24 hr apart). Most respondents (99%) indicated that they use melarsomine in conjunction with other therapies, including exercise restriction (81%), monthly heartworm preventive (75%), and doxycycline (77%). Of respondents who reported the use of melarsomine as part of firstline therapy, only 9.5% reported that they use melarsomine as a single-agent treatment. Only 1% of respondents reported that they 
HWD Cases with Clinical Signs
Next, respondents were asked to identify which of a provided list of options were components of their first-line treatment approach to cases of HWD with clinical signs, assuming no financial constraints Although most respondents reported that they recommend exercise restriction as a component of first-line HWD therapy for dogs with and without clinical signs, a sizable minority (12% and 19%, respectively) indicated that they do not. Current AHS guidelines state that exercise restriction during the treatment and recovery period of HWD is essential for minimizing cardiopulmonary complications such as pulmonary thromboembolism. 8, 12 A study of experimentally infected dogs who were either exercise-restricted or allowed moderate activity showed that dogs who were exerciserestricted took longer to exhibit clinical signs of HWD and developed less histologic evidence of pulmonary arterial vascular damage. 13 Exercise or strenuous activity increases blood flow to already damaged arterioles and capillary beds, resulting in further capillary wall destruction and leading to fibrotic change in the pulmonary beds. Subsequently, pulmonary vascular resistance can increase and cor pulmonale may result. 13, 14 If exercise restriction is not imposed during HWD treatment, it is possible that adverse events may be seen more frequently. Respondents who reported they do not recommend exercise restriction may be unaware of these risks.
Respondents may not recommend exercise restriction because they presume that owner compliance with such a recommendation would be low. The findings of this study reveal an opportunity to increase the utilization of exercise restriction, which is both inexpensive and risk-free.
A predominate component of first-line HWD therapy was reported to include monthly heartworm preventives. However, a sizable number of respondents (25%) reported that they do not include monthly heartworm preventives as part of HWD therapy.
The use of a macrocyclic lactone for 2-3 mo prior to melarsomine administration is recommended by the AHS to allow larvae to mature to an age typically susceptible to melarsomine (i.e., decrease the susceptibility gap) before melarsomine administration. 4, 8, 15 Alternatively, they may have concerns for anaphylactic reactions secondary to microfilarial death following administration of macrocyclic lactones or with historical diethylcarbamazine administration. 8, 16 The findings of this study reveal an opportunity to increase awareness of the value of heartworm preventive therapy as part of HWD treatment protocols, and raise awareness of strategies to mitigate the risk of anaphylactic reactions, among practicing veterinarians.
The use of doxycycline to kill Wolbachia, an endosymbiont of D immitis, is recommended by the AHS to decrease both heartworm fertility and transmission of infective stages to other dogs via the mosquito vector. 8, [17] [18] [19] [20] [21] [22] [23] When given within 1-2 mo following heartworm infection, doxycycline has been shown to reduce the number of third-and fourth-stage larvae in experimental studies. Respondents reported the use of aspirin as a component of first-line HWD therapy for dogs with (10%) and without clinical signs (3%). The current AHS guidelines do not recommend aspirin due to conflicting evidence to support its use and the potential for detrimental effects. 8 In one investigation, no difference in histopathologic lesion severity was identified between the lungs of experimentally infected heartworm-positive dogs treated with or without aspirin. 24 Another study of aspirin's effect on platelet adhesion to chronically damaged pulmonary arterioles among HWD dogs documented enhanced platelet adhesion to the damaged vascular surface after 4 days of therapy, but decreased platelet adhesion after 30 days, compared with untreated dogs. 25 Given the conflicting results of these studies, and the theory that high-dose aspirin may inhibit endothelial cell cyclooxygenase and cause vasoconstriction, thereby favoring platelet adhesion, aspirin is not currently recommended by the AHS for HWD treatment. 24 The majority of respondents cited financial constraints as the most common reason that first-line recommendations require modification. Interestingly, there was no evidence to support the idea that a three-dose melarsomine protocol was modified to a less expensive two-dose melarsomine protocol in a large number of cases in which financial concerns were cited. It is possible that the cost savings of reducing the number of melarsomine doses would be significant to many owners, while still allowing the use of a relatively fast-acting adulticide protocol.
Nearly all respondents in the present study reported that they elect slow-kill methods for the treatment of cases of HWD, regardless of the presence or absence of clinical signs, when first-line recommendations are declined. The combination of macrocyclic lactones and doxycycline has been shown to be adulticidal in dogs with both experimental and naturally acquired HWD, and the combination has been shown to work more efficiently than ivermectin alone. [20] [21] [22] [23] In addition, this combination slows D immitis larval development and causes deterioration of existing adult heartworms. 4 However, the slow-kill method is not recommended by the AHS because continuous monthly administration of ivermectin requires up to 36 mo for complete D immitis elimination, during which time continued pulmonary and cardiac damage occur. 9 In study dogs who were administered continuous monthly ivermectin 4 mo post infection, approximately 70% of worms were dead after 6 mo and 95.1%
were dead after 12 mo. 26 However, when ivermectin was started 8 mo post infection, the efficacy decreased dramatically, with only 56% of worms dead after 16 monthly doses. 26 There are no experimental studies to support the idea that the slow-kill method is safer, as- Finally, as with any survey-based study, accuracy depends upon candid subject response and accurate recall.
Conclusion
This study was conducted in an effort to advance our understand- 
